Astrocytoma medical therapy: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(23 intermediate revisions by the same user not shown)
Line 3: Line 3:
{{CMG}}; {{AE}} {{Fs}}
{{CMG}}; {{AE}} {{Fs}}
==Overview==
==Overview==
The optimal [[therapy]] for astrocytoma depends on the stage at [[diagnosis]]. [[Chemotherapy]] is recommended for children. [[Radiation]] and [[chemotherapy]] with [[stem cell transplant]] is recommended for adults with high grade astrocytoma.
The mainstay of treatment for [[low grade astrocytoma]] is wait and see approach, [[Radiation therapy|radiation]] therapy and [[chemotherapy]]. Treatment for [[anaplastic astrocytoma]] is [[radiotherapy]] with adjunctive [[chemotherapy]], [[Radiation therapy|radiotherapy]] alone and [[chemotherapy]] alone. Treatment for [[Glioblastoma multiforme|glioblastoma multiform]] is [[chemotherapy]] and [[Radiation therapy|radiotherapy]], [[Bevacizumab]], alternating electric fields and [[Carmustine]] polymer wafers.
 
==Medical Therapy==
==Medical Therapy==
* Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
* Post surgical medical therapy is recommended in all patients with astrocytoma tumor.
* Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
* Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
* Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].


=== Astrocytoma ===
=== Astrocytoma ===
* '''1 Grade 1 - Pilocytic astrocytoma'''
* '''1 Grade 1 and 2 - Low grade astrocytomas'''
** 1.1 '''Specific Organ system involved 1'''
** 1.1 Wait and see<ref name="pmid17469128">{{cite journal |vauthors=Ricard D, Kaloshi G, Amiel-Benouaich A, Lejeune J, Marie Y, Mandonnet E, Kujas M, Mokhtari K, Taillibert S, Laigle-Donadey F, Carpentier AF, Omuro A, Capelle L, Duffau H, Cornu P, Guillevin R, Sanson M, Hoang-Xuan K, Delattre JY |title=Dynamic history of low-grade gliomas before and after temozolomide treatment |journal=Ann. Neurol. |volume=61 |issue=5 |pages=484–90 |date=May 2007 |pmid=17469128 |doi=10.1002/ana.21125 |url=}}</ref><ref name="pmid18976072">{{cite journal |vauthors=Shaw EG, Berkey B, Coons SW, Bullard D, Brachman D, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta M |title=Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial |journal=J. Neurosurg. |volume=109 |issue=5 |pages=835–41 |date=November 2008 |pmid=18976072 |pmc=3833272 |doi=10.3171/JNS/2008/109/11/0835 |url=}}</ref>
*** 1.1.1 '''Adult'''
*** The wait and see approach is for young patient with complete or nearly complete [[tumor]] resection.
**** Preferred regimen (1): drug name 100 mg PO q12h for 10-21 days '''(Contraindications/specific instructions)'''
*** since the [[low grade astrocytoma]] will finally grow to [[high grade astrocytoma]], we should screen these patients with contrast [[MRI]] every 4 month.
**** Preferred regimen (2): drug name 500 mg PO q8h for 14-21 days
** 1.2 [[Radiation therapy]]<ref name="pmid16168780">{{cite journal |vauthors=van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, Malmström PO, Collette L, Piérart M, Mirimanoff R, Karim AB |title=Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial |journal=Lancet |volume=366 |issue=9490 |pages=985–90 |date=2005 |pmid=16168780 |doi=10.1016/S0140-6736(05)67070-5 |url=}}</ref><ref name="pmid26530266">{{cite journal |vauthors=Ryken TC, Parney I, Buatti J, Kalkanis SN, Olson JJ |title=The role of radiotherapy in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline |journal=J. Neurooncol. |volume=125 |issue=3 |pages=551–83 |date=December 2015 |pmid=26530266 |doi=10.1007/s11060-015-1948-1 |url=}}</ref>
**** Preferred regimen (3): drug name 500 mg q12h for 14-21 days
*** Immediate post [[surgery]] [[radiation therapy]] can reduce the progression rate.
**** Alternative regimen (1): drug name 500 mg PO q6h for 7–10 days
*** It doesn't affect survival since it cannot prevent transformation of [[low grade astrocytoma]] to [[high grade astrocytoma]].
**** Alternative regimen (2): drug name 500 mg PO q12h for 14–21 days
*** Preferred regimen: 50 t0 54 Gy
**** Alternative regimen (3): drug name 500 mg PO q6h for 14–21 days
** 1.3 Adjunctive [[chemotherapy]]<ref name="pmid28801186">{{cite journal |vauthors=van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM |title=Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study |journal=Lancet |volume=390 |issue=10103 |pages=1645–1653 |date=October 2017 |pmid=28801186 |pmc=5806535 |doi=10.1016/S0140-6736(17)31442-3 |url=}}</ref><ref name="pmid27050206">{{cite journal |vauthors=Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, Coons S, Ricci P, Bullard D, Brown PD, Stelzer K, Brachman D, Suh JH, Schultz CJ, Bahary JP, Fisher BJ, Kim H, Murtha AD, Bell EH, Won M, Mehta MP, Curran WJ |title=Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma |journal=N. Engl. J. Med. |volume=374 |issue=14 |pages=1344–55 |date=April 2016 |pmid=27050206 |pmc=5170873 |doi=10.1056/NEJMoa1500925 |url=}}</ref><ref name="pmid22851558">{{cite journal |vauthors=Shaw EG, Wang M, Coons SW, Brachman DG, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta MP |title=Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802 |journal=J. Clin. Oncol. |volume=30 |issue=25 |pages=3065–70 |date=September 2012 |pmid=22851558 |pmc=3732006 |doi=10.1200/JCO.2011.35.8598 |url=}}</ref>
*** 1.1.2 '''Pediatric'''
*** 1.3.1 [[Temozolomide]]
**** 1.1.2.1 (Specific population e.g. '''children < 8 years of age''')
*** 1.3.2 PVC ([[Procarbazine]], [[Lomustine]], [[Vincristine]])
***** Preferred regimen (1): drug name 50 mg/kg PO per day q8h (maximum, 500 mg per dose)
*** Based on previous studies, patients who get [[chemotherapy]] along with [[Radiation therapy|radiotherapy]] immediately after [[surgery]] has better outcome.
***** Preferred regimen (2): drug name 30 mg/kg PO per day in 2 divided doses (maximum, 500 mg per dose)
***** Alternative regimen (1): drug name10 mg/kg PO q6h (maximum, 500 mg per day)
***** Alternative regimen (2): drug name 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
***** Alternative regimen (3): drug name 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
**** 1.1.2.2 (Specific population e.g. '<nowiki/>'''''children < 8 years of age'''''')
***** Preferred regimen (1): drug name 4 mg/kg/day PO q12h（maximum, 100 mg per dose）
***** Alternative regimen (1): drug name 10 mg/kg PO q6h (maximum, 500 mg per day)
***** Alternative regimen (2): drug name 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
***** Alternative regimen (3): drug name 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
** 1.2 '''Specific Organ system involved 2'''
*** 1.2.1 '''Adult'''
**** Preferred regimen (1): drug name 500 mg PO q8h
*** 1.2.2 '''Pediatric'''
**** Preferred regimen (1): drug name 50 mg/kg/day PO q8h (maximum, 500 mg per dose)


* 2 '''Grade 2- Diffuse astrocytoma'''
** 2.1 '''Specific Organ system involved 1'''
**: '''Note (1):'''
**: '''Note (2)''':
**: '''Note (3):'''
*** 2.1.1 '''Adult'''
**** Parenteral regimen
***** Preferred regimen (1): drug name 2 g IV q24h for 14 (14–21) days
***** Alternative regimen (1): drug name 2 g IV q8h for 14 (14–21) days
***** Alternative regimen (2): drug name 18–24 MU/day IV q4h for 14 (14–21) days
**** Oral regimen
***** Preferred regimen (1): drug name 500 mg PO q8h for 14 (14–21) days
***** Preferred regimen (2): drug name 100 mg PO q12h for 14 (14–21) days
***** Preferred regimen (3): drug name 500 mg PO q12h for 14 (14–21) days
***** Alternative regimen (1): drug name 500 mg PO q6h for 7–10 days
***** Alternative regimen (2): drug name 500 mg PO q12h for 14–21 days
***** Alternative regimen (3):drug name 500 mg PO q6h for 14–21 days
*** 2.1.2 '''Pediatric'''
**** Parenteral regimen
***** Preferred regimen (1): drug name 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
***** Alternative regimen (1): drug name 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
***** Alternative regimen (2):  drug name 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day) '<nowiki/>'''''(Contraindications/specific instructions)''''''
**** Oral regimen
***** Preferred regimen (1):  drug name 50 mg/kg/day PO q8h for 14 (14–21) days  (maximum, 500 mg per dose)
***** Preferred regimen (2): drug name '''(for children aged ≥ 8 years)''' 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
***** Preferred regimen (3): drug name 30 mg/kg/day PO q12h for 14 (14–21) days  (maximum, 500 mg per dose)
***** Alternative regimen (1):  drug name 10 mg/kg PO q6h 7–10 days  (maximum, 500 mg per day)
***** Alternative regimen (2): drug name 7.5 mg/kg PO q12h for 14–21 days  (maximum, 500 mg per dose)
***** Alternative regimen (3): drug name 12.5 mg/kg PO q6h for 14–21 days  (maximum,500 mg per dose)
** 2.2  '<nowiki/>'''''Other Organ system involved 2''''''
**: '''Note (1):'''
**: '''Note (2)''':
**: '''Note (3):'''
*** 2.2.1 '''Adult'''
**** Parenteral regimen
***** Preferred regimen (1): drug name 2 g IV q24h for 14 (14–21) days
***** Alternative regimen (1): drug name 2 g IV q8h for 14 (14–21) days
***** Alternative regimen (2): drug name 18–24 MU/day IV q4h for 14 (14–21) days
**** Oral regimen
***** Preferred regimen (1): drug name 500 mg PO q8h for 14 (14–21) days
***** Preferred regimen (2): drug name 100 mg PO q12h for 14 (14–21) days
***** Preferred regimen (3): drug name 500 mg PO q12h for 14 (14–21) days
***** Alternative regimen (1): drug name 500 mg PO q6h for 7–10 days
***** Alternative regimen (2): drug name 500 mg PO q12h for 14–21 days
***** Alternative regimen (3):drug name 500 mg PO q6h for 14–21 days
*** 2.2.2 '''Pediatric'''
**** Parenteral regimen
***** Preferred regimen (1): drug name 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
***** Alternative regimen (1): drug name 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
***** Alternative regimen (2):  drug name 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day)
**** Oral regimen
***** Preferred regimen (1):  drug name 50 mg/kg/day PO q8h for 14 (14–21) days  (maximum, 500 mg per dose)
***** Preferred regimen (2): drug name 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
***** Preferred regimen (3): drug name 30 mg/kg/day PO q12h for 14 (14–21) days  (maximum, 500 mg per dose)
***** Alternative regimen (1):  drug name 10 mg/kg PO q6h 7–10 days  (maximum, 500 mg per day)
***** Alternative regimen (2): drug name 7.5 mg/kg PO q12h for 14–21 days  (maximum, 500 mg per dose)
***** Alternative regimen (3): drug name 12.5 mg/kg PO q6h for 14–21 days  (maximum,500 mg per dose)


===Chemotherapy===
* '''2 Grade 3 - [[Anaplastic astrocytoma]]'''
* [[Chemotherapy]] is a [[cancer]] treatment that uses [[drug]]s to stop the growth of [[cancer]] [[cell]]s, either by killing the [[cell]]s or by stopping them from dividing. When [[chemotherapy]] is taken by [[mouth]] or injected into a [[vein]] or [[muscle]], the [[drug]]s enter the [[bloodstream]] and can reach [[cancer]] [[cell]]s throughout the [[body]] (systemic [[chemotherapy]]). When [[chemotherapy]] is placed directly into the [[cerebrospinal fluid]], an [[organ]], or a [[body]] cavity such as the [[abdomen]], the [[drug]]s mainly affect [[cancer]] [[cell]]s in those areas (regional [[chemotherapy]]). Combination chemotherapy is the use of more than one anticancer drug.
** 2.1 [[Radiation therapy|Radiotherapy]]+ [[chemotherapy]] ([[Temozolomide]])<ref name="pmid26033545">{{cite journal |vauthors=Juratli TA, Lautenschläger T, Geiger KD, Pinzer T, Krause M, Schackert G, Krex D |title=Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients |journal=J. Neurooncol. |volume=124 |issue=2 |pages=197–205 |date=September 2015 |pmid=26033545 |doi=10.1007/s11060-015-1822-1 |url=}}</ref><ref name="pmid27401155">{{cite journal |vauthors=Shin JY, Diaz AZ |title=Anaplastic astrocytoma: prognostic factors and survival in 4807 patients with emphasis on receipt and impact of adjuvant therapy |journal=J. Neurooncol. |volume=129 |issue=3 |pages=557–565 |date=September 2016 |pmid=27401155 |doi=10.1007/s11060-016-2210-1 |url=}}</ref>
*Systemic [[chemotherapy]] is used in the treatment of children with astrocytoma. The way the [[chemotherapy]] is given depends on the type of [[tumor]] and where the [[tumor]] formed in the [[brain]] or [[spinal cord]].
*** Studies demonstrated that the combination of [[radiotherapy]] and [[chemotherapy]] with [[temozolomide]] is more effective.
** 2.2 [[Radiation therapy|Radiation]]  
** 2.3 [[Chemotherapy]]  
*** 2.3.1 [[Procarbazine]], [[Lomustine]], [[Vincristine]]
*** 2.3.2 [[Procarbazine]], [[Lomustine]], [[Temozolomide]]<ref name="pmid19901110">{{cite journal |vauthors=Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M |title=NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide |journal=J. Clin. Oncol. |volume=27 |issue=35 |pages=5874–80 |date=December 2009 |pmid=19901110 |doi=10.1200/JCO.2009.23.6497 |url=}}</ref><ref name="pmid27370396">{{cite journal |vauthors=Wick W, Roth P, Hartmann C, Hau P, Nakamura M, Stockhammer F, Sabel MC, Wick A, Koeppen S, Ketter R, Vajkoczy P, Eyupoglu I, Kalff R, Pietsch T, Happold C, Galldiks N, Schmidt-Graf F, Bamberg M, Reifenberger G, Platten M, von Deimling A, Meisner C, Wiestler B, Weller M |title=Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide |journal=Neuro-oncology |volume=18 |issue=11 |pages=1529–1537 |date=November 2016 |pmid=27370396 |pmc=5063521 |doi=10.1093/neuonc/now133 |url=}}</ref>


====High-dose Chemotherapy with Stem Cell Transplant====
* High-dose [[chemotherapy]] with [[stem cell]] [[transplant]] is a way of giving high doses of [[chemotherapy]] and replacing [[blood]] -forming [[cell]]s destroyed by the [[cancer]] treatment. [[Stem cell]]s (immature [[blood cell]]s) are removed from the [[blood]] or [[bone marrow]] of the [[patient]] or a [[donor]] and are frozen and stored. After the [[chemotherapy]] is completed, the stored [[stem cell]]s are thawed and given back to the patient through an infusion. These reinfused [[stem cell]]s grow into (and restore) the body's [[blood cell]]s.
* Treatment depends on the size and type of [[tumor]] and the child's general health. The goals of treatment may be to cure the [[tumor]], relieve symptoms, and improve [[brain]] function or the child's comfort
* Two related drugs have been shown to shrink or stabilize supependymal giant cell tumors: [[rapamycin]] and [[everolimus]]. These both belong to the [[mTOR]] inhibitor class of [[immunosuppressant]]s, and are both contraindicated in patients with severe [[infection]]s.
:* [[Rapamycin]] showed efficacy in five cases of SEGA in TSC patients, shrinking their [[tumor]] volumes by an average of 65%. However, after the [[drug]] was stopped, the [[tumor]]s regrew.
:* [[Everolimus]] which has a similar structure as [[rapamycin]], but with slightly increased bioavailability and shorter half-life, was studied in 28 patients with SEGA.  There was a significant reduction in SEGA size in 75% of the patients, and a mild improvement in their seizures. [[Everolimus]]  was approved for the treatment of SEGA by the US Food and Drug Administration (FDA) in October, 2010.
* Medicines used to treat primary [[brain tumor]]s in children include:
:* [[Corticosteroid]]s to reduce [[brain]] [[swelling]]
:* [[Diuretics]] (water pills) to reduce [[brain]] [[swelling]] and pressure
:* [[Anticonvulsant]]s to reduce or prevent [[seizure]]s
:* [[Pain]] medicines
* Comfort measures, safety measures, [[physical therapy]], occupational [[therapy]], and other such steps may be required to improve quality of life.
* Despite decades of therapeutic research, curative intervention is still nonexistent for high grade astrocytomas; patient care ultimately focuses on [[palliative]] management.


===Radiation Therapy===
* '''3 Grade 4 - [[Glioblastoma multiforme|Glioblastoma multiform]]'''
* [[Radiation therapy]] is a [[cancer]] treatment that uses high-energy x-rays or other types of [[radiation]] to kill [[cancer cell]]s or keep them from growing. There are two types of [[radiation therapy]]:
** 3.1 [[Chemotherapy]] (± [[Radiation therapy|radiotherapy]])<ref name="pmid15758009">{{cite journal |vauthors=Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO |title=Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma |journal=N. Engl. J. Med. |volume=352 |issue=10 |pages=987–96 |date=March 2005 |pmid=15758009 |doi=10.1056/NEJMoa043330 |url=}}</ref><ref name="pmid27172136">{{cite journal |vauthors=Kole AJ, Park HS, Yeboa DN, Rutter CE, Corso CD, Aneja S, Lester-Coll NH, Mancini BR, Knisely JP, Yu JB |title=Concurrent chemoradiotherapy versus radiotherapy alone for "biopsy-only" glioblastoma multiforme |journal=Cancer |volume=122 |issue=15 |pages=2364–70 |date=August 2016 |pmid=27172136 |doi=10.1002/cncr.30063 |url=}}</ref>
** External [[radiation therapy]] uses a machine outside the body to send [[radiation]] toward the [[cancer]].
*** 3.1.1 [[Temozolomide]]
** Internal [[radiation therapy]] uses a radioactive substance sealed in [[needle]]s, seeds, wires, or [[catheter]]s that are placed directly into or near the [[cancer]].
** 3.2 [[Bevacizumab]]<ref name="pmid21135282">{{cite journal |vauthors=Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, Phuphanich S, Black K, Peak S, Green RM, Spier CE, Kolevska T, Polikoff J, Fehrenbacher L, Elashoff R, Cloughesy T |title=Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme |journal=J. Clin. Oncol. |volume=29 |issue=2 |pages=142–8 |date=January 2011 |pmid=21135282 |pmc=3058273 |doi=10.1200/JCO.2010.30.2729 |url=}}</ref>
* External [[radiation therapy]] is used to treat astrocytoma in children. The way the [[radiation therapy]] is given depends on the type of [[tumor]] and where the [[tumor]] formed in the [[brain]] or [[spinal cord]].[[Radiation therapy]] to the [[brain]] can affect growth and development in young children. Certain ways of giving [[radiation therapy]] can lessen the damage to healthy [[brain]] tissue:
*** A [[Monoclonal antibodies|monoclonal antibody]] which bind to [[VEGF]] and inactivate it.
** Conformal [[radiation therapy]] uses a computer to make a 3-dimensional (3-D) picture of the [[tumor]] and shapes the [[radiation]] beams to fit the [[tumor]]. This allows a high dose of [[radiation]] to reach the [[tumor]] and causes less damage to normal [[tissue]] around the [[tumor]].
** 3.3 Alternating electric fields<ref name="pmid22608262">{{cite journal |vauthors=Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbalý V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH |title=NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality |journal=Eur. J. Cancer |volume=48 |issue=14 |pages=2192–202 |date=September 2012 |pmid=22608262 |doi=10.1016/j.ejca.2012.04.011 |url=}}</ref>
** Intensity-modulated [[radiation therapy]] (IMRT) uses images created by a computer that show the size and shape of the [[tumor]]. Thin beams of [[radiation]] of different strengths are aimed at the [[tumor]] from many angles.
*** A portable device which will be placed on the [[scalp]] for generating TT fields. The combination of this device with [[Temozolomide]] will significantly increase survival.
** Stereotactic [[radiation therapy]] uses a rigid head frame attached to the [[skull]] to aim [[radiation]] directly to the [[tumor]], causing less damage to normal [[tissue]] around the [[tumor]]. The total dose of [[radiation]] is divided into several smaller doses given over several days. This procedure is also called stereotactic external-beam [[radiation therapy]] and stereotaxic [[radiation therapy]].
** 3.4 [[Carmustine]] polymer wafers<ref name="pmid12672279">{{cite journal |vauthors=Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J, Ram Z |title=A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma |journal=Neuro-oncology |volume=5 |issue=2 |pages=79–88 |date=April 2003 |pmid=12672279 |pmc=1920672 |doi=10.1093/neuonc/5.2.79 |url=}}</ref>
** Proton beam [[radiation therapy]] is a type of high-energy, external [[radiation therapy]] that uses streams of [[proton]]s (small, positively-charged particles of matter) to kill [[tumor]] cells.
*** Implanted at the time of [[surgery]].
* For children younger than 3 years, [[chemotherapy]] may be given instead, to delay or reduce the need for [[radiation therapy]].<ref name="NCI">{{cite web | title = National Caner Institute Astrocytoma| url =http://www.cancer.gov/types/brain/hp/child-astrocytoma-treament-pdq#cit/section_1.19 }}</ref>
*** Can be used in combination with [[chemotherapy]] or [[radiation]].
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}

Latest revision as of 19:19, 14 January 2019

Astrocytoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Astrocytoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Study

Case #1

Astrocytoma medical therapy On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Astrocytoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Astrocytoma medical therapy

CDC on Astrocytoma medical therapy

Astrocytoma medical therapy in the news

Blogs on Astrocytoma medical therapy

Directions to Hospitals Treating Astrocytoma

Risk calculators and risk factors for Astrocytoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview

The mainstay of treatment for low grade astrocytoma is wait and see approach, radiation therapy and chemotherapy. Treatment for anaplastic astrocytoma is radiotherapy with adjunctive chemotherapy, radiotherapy alone and chemotherapy alone. Treatment for glioblastoma multiform is chemotherapy and radiotherapy, Bevacizumab, alternating electric fields and Carmustine polymer wafers.

Medical Therapy

  • Post surgical medical therapy is recommended in all patients with astrocytoma tumor.

Astrocytoma



References

  1. ↑ Ricard D, Kaloshi G, Amiel-Benouaich A, Lejeune J, Marie Y, Mandonnet E, Kujas M, Mokhtari K, Taillibert S, Laigle-Donadey F, Carpentier AF, Omuro A, Capelle L, Duffau H, Cornu P, Guillevin R, Sanson M, Hoang-Xuan K, Delattre JY (May 2007). "Dynamic history of low-grade gliomas before and after temozolomide treatment". Ann. Neurol. 61 (5): 484–90. doi:10.1002/ana.21125. PMID 17469128.
  2. ↑ Shaw EG, Berkey B, Coons SW, Bullard D, Brachman D, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta M (November 2008). "Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial". J. Neurosurg. 109 (5): 835–41. doi:10.3171/JNS/2008/109/11/0835. PMC 3833272. PMID 18976072.
  3. ↑ van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, Malmström PO, Collette L, Piérart M, Mirimanoff R, Karim AB (2005). "Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial". Lancet. 366 (9490): 985–90. doi:10.1016/S0140-6736(05)67070-5. PMID 16168780.
  4. ↑ Ryken TC, Parney I, Buatti J, Kalkanis SN, Olson JJ (December 2015). "The role of radiotherapy in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline". J. Neurooncol. 125 (3): 551–83. doi:10.1007/s11060-015-1948-1. PMID 26530266.
  5. ↑ van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens W, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM (October 2017). "Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study". Lancet. 390 (10103): 1645–1653. doi:10.1016/S0140-6736(17)31442-3. PMC 5806535. PMID 28801186. Vancouver style error: initials (help)
  6. ↑ Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, Coons S, Ricci P, Bullard D, Brown PD, Stelzer K, Brachman D, Suh JH, Schultz CJ, Bahary JP, Fisher BJ, Kim H, Murtha AD, Bell EH, Won M, Mehta MP, Curran WJ (April 2016). "Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma". N. Engl. J. Med. 374 (14): 1344–55. doi:10.1056/NEJMoa1500925. PMC 5170873. PMID 27050206.
  7. ↑ Shaw EG, Wang M, Coons SW, Brachman DG, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta MP (September 2012). "Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802". J. Clin. Oncol. 30 (25): 3065–70. doi:10.1200/JCO.2011.35.8598. PMC 3732006. PMID 22851558.
  8. ↑ Juratli TA, Lautenschläger T, Geiger KD, Pinzer T, Krause M, Schackert G, Krex D (September 2015). "Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients". J. Neurooncol. 124 (2): 197–205. doi:10.1007/s11060-015-1822-1. PMID 26033545.
  9. ↑ Shin JY, Diaz AZ (September 2016). "Anaplastic astrocytoma: prognostic factors and survival in 4807 patients with emphasis on receipt and impact of adjuvant therapy". J. Neurooncol. 129 (3): 557–565. doi:10.1007/s11060-016-2210-1. PMID 27401155.
  10. ↑ Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M (December 2009). "NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide". J. Clin. Oncol. 27 (35): 5874–80. doi:10.1200/JCO.2009.23.6497. PMID 19901110.
  11. ↑ Wick W, Roth P, Hartmann C, Hau P, Nakamura M, Stockhammer F, Sabel MC, Wick A, Koeppen S, Ketter R, Vajkoczy P, Eyupoglu I, Kalff R, Pietsch T, Happold C, Galldiks N, Schmidt-Graf F, Bamberg M, Reifenberger G, Platten M, von Deimling A, Meisner C, Wiestler B, Weller M (November 2016). "Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide". Neuro-oncology. 18 (11): 1529–1537. doi:10.1093/neuonc/now133. PMC 5063521. PMID 27370396.
  12. ↑ Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (March 2005). "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma". N. Engl. J. Med. 352 (10): 987–96. doi:10.1056/NEJMoa043330. PMID 15758009.
  13. ↑ Kole AJ, Park HS, Yeboa DN, Rutter CE, Corso CD, Aneja S, Lester-Coll NH, Mancini BR, Knisely JP, Yu JB (August 2016). "Concurrent chemoradiotherapy versus radiotherapy alone for "biopsy-only" glioblastoma multiforme". Cancer. 122 (15): 2364–70. doi:10.1002/cncr.30063. PMID 27172136.
  14. ↑ Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, Phuphanich S, Black K, Peak S, Green RM, Spier CE, Kolevska T, Polikoff J, Fehrenbacher L, Elashoff R, Cloughesy T (January 2011). "Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme". J. Clin. Oncol. 29 (2): 142–8. doi:10.1200/JCO.2010.30.2729. PMC 3058273. PMID 21135282.
  15. ↑ Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbalý V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH (September 2012). "NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality". Eur. J. Cancer. 48 (14): 2192–202. doi:10.1016/j.ejca.2012.04.011. PMID 22608262.
  16. ↑ Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J, Ram Z (April 2003). "A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma". Neuro-oncology. 5 (2): 79–88. doi:10.1093/neuonc/5.2.79. PMC 1920672. PMID 12672279.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Astrocytoma_medical_therapy&oldid=1535661"